United States Biotechnology & Medical Research

Foghorn Therapeutics Inc. (FHTX)

Track

Track

Ticker: FHTX Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Foghorn Therapeutics Inc.. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Costa Carlos Chief People Officer Officer
Transaction date
Planned sale
Price
418.58
Quantity 62,580 +37.0%
Value US$3,468,063
Costa Carlos Chief People Officer Officer
Transaction date
Planned sale
Price
252.39
Quantity 55,524 +3.7%
Value US$2,431,210
Costa Carlos Chief People Officer Officer
Transaction date
Planned sale
Price
489.78
Quantity 53,847 -15.9%
Value US$804,698
Costa Carlos Chief People Officer Officer
Transaction date
Planned sale
Price
10.04
Quantity 10,272 -100.0%
Value US$103,131
Costa Carlos Chief People Officer Officer
Transaction date
Planned sale
Price
10.00
Quantity 400 -100.0%
Value US$4,000
CARLOS COSTA Officer Officer
Transaction date
Proposed sale
Price
9.72
Quantity 98,648
Value US$958,859
Bellon Steven F. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
9.50
Quantity 20,000 -16.4%
Value US$190,000
STEVEN BELLON Officer Officer
Transaction date
Proposed sale
Price
7.53
Quantity 20,000
Value US$150,600
2.3
Cavalie Fanny Chief Strategy/Bus Ops Officer Officer
Transaction date
Sale
Price
6.56
Quantity 11,000 -12.6%
Value US$72,134
Agresta Samuel Chief Medical Officer Officer
Transaction date
Sale
Price
8.25
Quantity 311,297 -100.0%
Value US$2,568,200
SAMUEL AGRESTA Officer Officer
Transaction date
Proposed sale
Price
8.25
Quantity 311,297
Value US$2,568,200
3.0
DECICCO CARL Chief Scientific Officer Officer
Transaction date
Purchase
Price
16.00
Quantity 5,500 +2.2%
Value US$88,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2024-09-24 2024-09-23 PlS Planned sale
Costa Carlos

Chief People Officer

Officer
62,580 +37.0%
418.58
US$3,468,063 		62,580 +37.0% 418.58 US$3,468,063
2024-09-24 2024-09-20 PlS Planned sale
Costa Carlos

Chief People Officer

Officer
55,524 +3.7%
252.39
US$2,431,210 		55,524 +3.7% 252.39 US$2,431,210
2024-09-20 2024-09-18 PlS Planned sale
Costa Carlos

Chief People Officer

Officer
53,847 -15.9%
489.78
US$804,698 		53,847 -15.9% 489.78 US$804,698
2024-09-18 2024-09-17 PlS Planned sale
Costa Carlos

Chief People Officer

Officer
10,272 -100.0%
10.04
US$103,131 		10,272 -100.0% 10.04 US$103,131
2024-09-18 2024-09-16 PlS Planned sale
Costa Carlos

Chief People Officer

Officer
400 -100.0%
10.00
US$4,000 		400 -100.0% 10.00 US$4,000
2024-09-16 2024-09-16 PrS Proposed sale
CARLOS COSTA

Officer

Officer
98,648
9.72
US$958,859 		98,648 9.72 US$958,859
2024-09-11 2024-09-09 PlS Planned sale
Bellon Steven F.

Chief Scientific Officer

Officer
20,000 -16.4%
9.50
US$190,000 		20,000 -16.4% 9.50 US$190,000
2024-09-09 2024-09-09 PrS Proposed sale
STEVEN BELLON

Officer

Officer
20,000
7.53
US$150,600 		20,000 7.53 US$150,600
2024-03-12 2024-03-11 S Sale
2.3
Cavalie Fanny

Chief Strategy/Bus Ops Officer

Officer
11,000 -12.6%
6.56
US$72,134 		11,000 -12.6% 6.56 US$72,134
2023-08-18 2023-08-16 S Sale
Agresta Samuel

Chief Medical Officer

Officer
311,297 -100.0%
8.25
US$2,568,200 		311,297 -100.0% 8.25 US$2,568,200
2023-08-16 2023-08-16 PrS Proposed sale
SAMUEL AGRESTA

Officer

Officer
311,297
8.25
US$2,568,200 		311,297 8.25 US$2,568,200
2020-10-29 2020-10-27 B Purchase
3.9
Flagship Ventures Fund V General Partner LLC
Large shareholder
50,000 +2.8%
16.00
US$800,000 		50,000 +2.8% 16.00 US$800,000
2020-10-29 2020-10-27 B Purchase
3.9
Flagship Ventures Fund V General Partner LLC
Large shareholder
50,000 +3.5%
16.00
US$800,000 		50,000 +3.5% 16.00 US$800,000
2020-10-29 2020-10-27 B Purchase
3.9
Flagship Ventures Fund V General Partner LLC
Large shareholder
50,000 +0.5%
16.00
US$800,000 		50,000 +0.5% 16.00 US$800,000
2020-10-29 2020-10-27 B Purchase
3.0
DECICCO CARL

Chief Scientific Officer

Officer
5,500 +2.2%
16.00
US$88,000 		5,500 +2.2% 16.00 US$88,000
2020-10-28 2020-10-27 B Purchase
3.1
Abu Dhabi Investment Authority

Former 10% Owner
150,000 +13.9%
16.00
US$2,400,000 		150,000 +13.9% 16.00 US$2,400,000
Explore more

More insider trading research around Foghorn Therapeutics Inc.

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America